ANAPTYSBIO, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $3.38M.
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $9.72M.
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-06-30 was $50.15M.
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for the quarter ending 2025-03-31 was $5.38M, a 89.25% decline year-over-year.
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for fiscal 2025 was $68.63M.
- ANAPTYSBIO, INC. treasury stock, value, acquired, cost method for fiscal 2023 was $50.00M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2025-12-31 | $3.38M 10-K · filed 2026-03-03 | $68.63M 10-K · filed 2026-03-03 |
| 2025-09-30 | $9.72M 10-K · filed 2026-03-03 | |
| 2025-06-30 | $50.15M 10-K · filed 2026-03-03 | |
| 2025-03-31 | $5.38M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $50.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $50.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $50.00M 10-Q · filed 2024-05-09 | $61.54M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $50.00M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2023-06-30 | $11.54M 10-K · filed 2025-02-27 | |
| 2023-03-31 | $38.46M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |